Details of the Drug

General Information of Drug (ID: DM4O2Z7)

Drug Name
Cyclophosphamide
Synonyms
ASTA; Ciclofosfamida; Ciclophosphamide; Clafen; Claphene; Cycloblastin; Cyclophosphamid; Cyclophosphamides; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cytophosphan; Cytophosphane; Cytoxan; Endoxan; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Mitoxan; Neosar; Procytox; Revimmune; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; Ciclophosphamide [INN]; Cyclophosphamide Sterile; Cyclophosphamide anhydrous; Cyklofosfamid [Czech]; Cytoxan Lyoph; Endoxan R; Lyophilized Cytoxan; Zyklophosphamid [German]; ASTA B518; Asta B 518; B 518; C 0768; CB 4564; SK 20501; B-518; CB-4564; Ciclofosfamida [INN-Spanish]; Cyclophosphamide (INN); Cyclophosphamide (TN); Cyclophosphamide (anhydrous form); Cyclophosphamide (anhydrous); Cyclophosphamidum [INN-Latin]; Cytoxan (TN); Endoxan (TN); Endoxan-Asta; Neosar (TN); Occupation, cyclophosphamide exposure; Procytox (TN); Revimmune (TN); Bis(2-Chloroethyl)phosphami de cyclic propanolamide; Bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; D,L-Cyclophosphamide; Cyclophosphamide, (+-)-Isomer; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; (+-)-Cyclophosphamide; (-)-Cyclophosphamide; (RS)-Cyclophosphamide; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; 4-Hydroxy-cyclophosphan-mamophosphatide
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [1], [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 261.079
Topological Polar Surface Area (xlogp) 0.6
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
74% of drug becomes completely available to its intended biological destination(s) [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 1.1 mL/min/kg [6]
Elimination
6.5% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 3 - 12 hours [6]
Metabolism
The drug is metabolized via the liver [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 19.15051 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.87% [6]
Vd
The volume of distribution (Vd) of drug is 30-50 L [8]
Water Solubility
The ability of drug to dissolve in water is measured as 40 mg/mL [4]
Chemical Identifiers
Formula
C7H15Cl2N2O2P
IUPAC Name
N,N-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
Canonical SMILES
C1CNP(=O)(OC1)N(CCCl)CCCl
InChI
InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)
InChIKey
CMSMOCZEIVJLDB-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2907
ChEBI ID
CHEBI:4027
CAS Number
50-18-0
DrugBank ID
DB00531
TTD ID
D0CT9C
VARIDT ID
DR00425
INTEDE ID
DR0391
ACDINA ID
D00157

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [9], [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [13]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [14]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [15]
Cytochrome P450 2B6 (CYP2B6)
Main DME 		DEPKLMQ CP2B6_HUMAN Substrate [16]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [17]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [18]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [15]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Cyclophosphamide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
LEE011 DMMX75K Moderate Decreased metabolism of Cyclophosphamide caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [87]
Coadministration of a Drug Treating the Disease Different from Cyclophosphamide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Cyclophosphamide caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [88]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Cyclophosphamide and Repaglinide. Acute diabete complication [5A2Y] [89]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Cyclophosphamide and Glibenclamide. Acute diabete complication [5A2Y] [89]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Cyclophosphamide and Tolazamide. Acute diabete complication [5A2Y] [89]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Cyclophosphamide and Nateglinide. Acute diabete complication [5A2Y] [89]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Cyclophosphamide and Glipizide. Acute diabete complication [5A2Y] [89]
Arn-509 DMT81LZ Moderate Increased metabolism of Cyclophosphamide caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [90]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Cyclophosphamide and Inotersen. Amyloidosis [5D00] [90]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Cyclophosphamide and Roflumilast. Asthma [CA23] [90]
Ofloxacin DM0VQN3 Minor Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [91]
Ciprofloxacin XR DM2NLS9 Minor Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [91]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Cyclophosphamide caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [92]
Trovafloxacin DM6AN32 Minor Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Trovafloxacin. Bacterial infection [1A00-1C4Z] [91]
Gemifloxacin DMHT34O Minor Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [91]
Norfloxacin DMIZ6W2 Minor Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [91]
ABT-492 DMJFD2I Minor Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [91]
Levofloxacin DMS60RB Minor Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [91]
Lomefloxacin DMVRH9C Minor Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [91]
Alpelisib DMEXMYK Moderate Increased metabolism of Cyclophosphamide caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [93]
Atracurium DM42HXN Moderate Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Atracurium. Corneal disease [9A76-9A78] [94]
Mivacurium DM473VD Moderate Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Mivacurium. Corneal disease [9A76-9A78] [94]
Pancuronium DMB0VY8 Moderate Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Pancuronium. Corneal disease [9A76-9A78] [94]
MK-8228 DMOB58Q Moderate Decreased metabolism of Cyclophosphamide caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [95]
Aprepitant DM053KT Moderate Decreased metabolism of Cyclophosphamide caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [96]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Cyclophosphamide caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [97]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Cyclophosphamide caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [98]
Cenobamate DMGOVHA Moderate Increased metabolism of Cyclophosphamide caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [99]
Stiripentol DMMSDOY Moderate Decreased metabolism of Cyclophosphamide caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [100]
Rufinamide DMWE60C Moderate Increased metabolism of Cyclophosphamide caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [90]
Phenobarbital DMXZOCG Minor Increased metabolism of Cyclophosphamide caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [101]
Carbamazepine DMZOLBI Moderate Increased metabolism of Cyclophosphamide caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [102]
Amphotericin B DMTAJQE Moderate Increased risk of nephrotoxicity by the combination of Cyclophosphamide and Amphotericin B. Fungal infection [1F29-1F2F] [88]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Cyclophosphamide caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [103]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Cyclophosphamide caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [103]
Darunavir DMN3GCH Moderate Decreased metabolism of Cyclophosphamide caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [104]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Cyclophosphamide caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [88]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Cyclophosphamide and Teriflunomide. Hyper-lipoproteinaemia [5C80] [105]
Givosiran DM5PFIJ Moderate Increased risk of nephrotoxicity by the combination of Cyclophosphamide and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [88]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Cyclophosphamide caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [106]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Cyclophosphamide and Denosumab. Low bone mass disorder [FB83] [107]
Crizotinib DM4F29C Moderate Decreased metabolism of Cyclophosphamide caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [88]
PF-06463922 DMKM7EW Moderate Increased metabolism of Cyclophosphamide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [108]
IPI-145 DMWA24P Moderate Decreased metabolism of Cyclophosphamide caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [109]
Clofarabine DMCVJ86 Moderate Increased risk of nephrotoxicity by the combination of Cyclophosphamide and Clofarabine. Mature B-cell lymphoma [2A85] [110]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Cyclophosphamide and Thalidomide. Multiple myeloma [2A83] [111]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Cyclophosphamide and Tecfidera. Multiple sclerosis [8A40] [112]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Cyclophosphamide and Siponimod. Multiple sclerosis [8A40] [88]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Cyclophosphamide and Fingolimod. Multiple sclerosis [8A40] [113]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Cyclophosphamide and Ocrelizumab. Multiple sclerosis [8A40] [114]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Cyclophosphamide and Ozanimod. Multiple sclerosis [8A40] [90]
Imatinib DM7RJXL Moderate Decreased metabolism of Cyclophosphamide caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [115]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Cyclophosphamide and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [116]
Prasugrel DM7MT6E Minor Decreased metabolism of Cyclophosphamide caused by Prasugrel mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [90]
Modafinil DMYILBE Minor Increased metabolism of Cyclophosphamide caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [117]
Bupropion DM5PCS7 Moderate Decreased metabolism of Cyclophosphamide caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [118]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Cyclophosphamide caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [119]
Abametapir DM2RX0I Moderate Decreased metabolism of Cyclophosphamide caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [120]
Lefamulin DME6G97 Moderate Decreased metabolism of Cyclophosphamide caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [121]
Enzalutamide DMGL19D Moderate Increased metabolism of Cyclophosphamide caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [122]
Bosentan DMIOGBU Moderate Increased metabolism of Cyclophosphamide caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [123]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Cyclophosphamide and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [124]
Gatifloxacin DMSL679 Minor Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [91]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Cyclophosphamide and Canakinumab. Rheumatoid arthritis [FA20] [125]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Cyclophosphamide and Rilonacept. Rheumatoid arthritis [FA20] [125]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Cyclophosphamide and Golimumab. Rheumatoid arthritis [FA20] [126]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Cyclophosphamide and Leflunomide. Rheumatoid arthritis [FA20] [105]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Cyclophosphamide when combined with Anthrax vaccine. Sepsis [1G40-1G41] [127]
Pitolisant DM8RFNJ Moderate Increased metabolism of Cyclophosphamide caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [90]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Cyclophosphamide caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [128]
Vecuronium DMP0UK2 Moderate Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Vecuronium. Tonus and reflex abnormality [MB47] [94]
Cisatracurium DMUZPJ5 Moderate Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Cisatracurium. Tonus and reflex abnormality [MB47] [94]
Rocuronium DMY9BMK Moderate Additive neuromuscular blocking effects by the combination of Cyclophosphamide and Rocuronium. Tonus and reflex abnormality [MB47] [94]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Cyclophosphamide and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [124]
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of Cyclophosphamide and Azathioprine. Transplant rejection [NE84] [129]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Cyclophosphamide and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [124]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Cyclophosphamide and Tolbutamide. Type 2 diabetes mellitus [5A11] [89]
Cinoxacin DM4EWNS Minor Decreased absorption of Cyclophosphamide due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [91]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Cyclophosphamide and Plazomicin. Urinary tract infection [GC08] [88]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Cyclophosphamide and Ganciclovir. Virus infection [1A24-1D9Z] [88]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Cyclophosphamide and Valganciclovir. Virus infection [1A24-1D9Z] [88]
⏷ Show the Full List of 80 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Sodium stearyl fumarate E00545 23665634 lubricant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Cyclophosphamide 25 mg capsule 25 mg Oral Capsule Oral
Cyclophosphamide 50 mg capsule 50 mg Oral Capsule Oral
Cyclophosphamide 25 mg tablet 25 mg Oral Tablet Oral
Cyclophosphamide 50 mg tablet 50 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7154).
2 Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
9 O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
10 Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells. Cancer Res. 1986 Oct;46(10):5029-34.
11 Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4). AAPS J. 2010 Sep;12(3):300-8.
12 Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models. Exp Anim. 2018 Feb 9;67(1):71-82.
13 CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
14 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
15 Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
16 The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):814-22.
17 Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
18 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
19 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
20 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
21 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
22 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
23 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
24 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
25 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
26 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
27 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
28 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
29 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
30 Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
31 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
32 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
33 CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
34 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
35 Drug Interactions Flockhart Table
36 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
37 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
38 Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
39 Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
40 Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
41 CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
42 Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
43 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
44 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
45 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
46 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
47 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
48 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
49 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
50 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
51 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
52 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
53 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
54 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
55 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
56 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
57 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
58 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
59 Drugs that may have potential CYP2B6 interactions.
60 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
61 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
62 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
63 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
64 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
65 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
66 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
67 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
68 Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
69 Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
70 ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
71 The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
72 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
73 Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
74 P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
75 Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
76 Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J. 2002 Feb 1;361(Pt 3):497-503.
77 Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
78 Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
79 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
80 Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
81 Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
82 DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
83 Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
84 Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
85 Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.
86 Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts: characterization of mono-alkylated and cross-linked products fr... Chem Biol Interact. 1990;73(2-3):183-94.
87 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
88 Cerner Multum, Inc. "Australian Product Information.".
89 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
90 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
91 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
92 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
93 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
94 Multum Information Services, Inc. Expert Review Panel.
95 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
96 Charasson V, Haaz MC, Robert J "Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan." Drug Metab Dispos 30 (2002): 731-733. [PMID: 12019202]
97 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
98 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
99 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
100 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
101 Garattini S, Spreafico F "Some examples of interactions between drugs in cancer chemotherapy." Antibiot Chemother 23 (1978): 283-94. [PMID: 348085]
102 Chang TK, Yu L, Maurel P, Waxman DJ "Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines." Cancer Res 57 (1997): 1946-54. [PMID: 9157990]
103 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
104 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
105 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
106 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
107 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
108 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
109 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
110 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
111 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
112 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
113 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
114 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
115 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
116 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
117 Product Information. Provigil (modafinil). Cephalon, Inc, West Chester, PA.
118 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
119 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
120 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
121 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
122 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
123 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
124 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
125 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
126 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
127 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
128 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
129 Shaunak S, Munro JM, Weinbren K, Walport MJ, Cox TM "Cyclophosphamide-induced liver necrosis: a possible interaction with azathioprine." Q J Med 67 (1988): 309-17. [PMID: 3060893]